Cytokinetics shareholders double authorized shares to 326M; approve equity plan amendment

CYTOKINETICS INC

Authorized common stock increased from 163M to 326M shares, approved with 107.3M votes for, 3.0M against.
Equity incentive plan amended to add 5.0M authorized shares and cap non-executive director grants ($1M annual, $1.25M initial).
Elected Class III directors John T. Henderson, B. Lynne Parshall, and Muna Bhanji with majority support.
Ratified Ernst & Young as independent auditor for FY2025 with 110.3M votes for.
Advisory vote on executive compensation passed with 96.8M votes for, 4.6M against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.